Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. We're very pleased to have Regeneron this morning. From the company, we have Israel Lowy, who is Senior Vice President, Translational and Clinical Sciences, Oncology; and Andres Sirulnik, who is Senior Vice President, Translational and Clinical Sciences, Hematology.
Before we get started, I'm going to turn it over to Justin Holko from the IR team, and then we'll dive into Q&A.
Thank you, Terence. Before we begin, I'd like to remind you that remarks made on today's event will include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement. A more complete description of these and other material risks can be found in Regeneron's SEC filings. We do not undertake
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |